Active Infection & Immunity Cancer

Understanding the CD28-CTLA-4 pathway: a thermostat for T cell immunity

In plain English

AI plain-English summary

The body's immune system relies on a molecular thermostat—a set of interacting proteins that dial T cell activity up or down, and when it breaks, the result is either crippled infection defences or the body attacking itself. This project tackles a fundamental gap in immunology: how the CD28, CTLA-4, and PD-1 pathways work together as an integrated control system. Scientists know the individual parts—the receptors CD28 and CTLA-4, their ligands CD80 and CD86, and the PD-1 pathway—but not how their different binding strengths, speeds, and competition for partners collectively tune immune responses. Without this understanding, efforts to manipulate these pathways therapeutically remain partly guesswork. The research is fundamental science, not applied drug development. It will measure the biophysical properties of these molecular interactions, test how natural and engineered changes alter T cell behaviour in cells and animals, and build mathematical models that predict system-level outcomes. If successful, it could reveal why certain immune checkpoint inhibitors work in some patients but not others, and provide a rational framework for designing more precise immunotherapies—for cancer, autoimmune disease, or transplant rejection. Past fundamental work on this same pathway directly enabled today's blockbuster cancer immunotherapies.

View original technical description
The CD28-CTLA-4 pathway controls T cell immune responses to both foreign and self-antigens, where loss of CD28 compromises adaptive immunity and loss of CTLA-4 causes fatal autoimmunity. The system is regulated by two distinct ligands CD80 and CD86, which bind with different affinity, avidity and valency characteristics to CD28 and CTLA-4. The binding of another ligand (PD-L1) to CD80, alters these characteristics and directly connects CD28, CTLA-4 and CD80 to the PD-1 pathway. Despite this critical position in controlling immunity, the fundamental mechanisms underpinning these pathways remain poorly understood. In this proposal we hypothesise that the integrated CD28-CTLA-4-PD-1 pathway represents a tunable "thermostat" that is regulated by a series of ligand-receptor interactions, competitions and feedbacks that control T cell outcomes. We propose to: a) Understand how biophysical characteristics of ligand-receptor interactions control pathway behaviour, by acting in concert. b) Determine how natural and engineered changes in these biophysical characteristics alter T cell responses in vitro and in vivo. c) Generate mathematical models to predict outcomes and look for emergent behaviours. We therefore aim to provide a fully integrated view of how this essential immune regulatory system works, from molecular detail through to immune function.

View the original record at the funder ↗

Researchers

David Sansom (EPMC Awardee)Lucy Walker (EPMC Awardee)Michael Meyer-Hermann (EPMC Awardee)Sahamoddin Khailaie (EPMC Awardee)

Related Research

Grants with similar aims, by meaning.

Towards an integrated understanding of the CD28/CTLA4 immune checkpoint in the regulation of autoimmunity
What is the molcular basis of CTLA-4 trans-endocytosis?
Understanding the relationship between clathrin-mediated endocytosis and transendocytosis of CTLA-4: cell biology at the heart of immune regulation.
Unravelling the CTLA-4 immune checkpoint: from cell biology to clinical application.
Understanding affinity variation in the CD28/ CTLA-4 pathway and its impact on immune function.

Original classification

Discovery Award

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.